B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients

[1]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[2]  D. de Jong,et al.  Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma , 2017, PloS one.

[3]  A. McConnachie,et al.  Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial , 2016, The Lancet.

[4]  W. Oyen,et al.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  W. Lems,et al.  Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study , 2015, Arthritis Research & Therapy.

[6]  G. V. van Dongen,et al.  Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  R. Boellaard,et al.  89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[8]  R. Caporali,et al.  B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers , 2014, BioMed research international.

[9]  Roel Wierts,et al.  Multicenter Harmonization of 89Zr PET/CT Performance , 2014, The Journal of Nuclear Medicine.

[10]  V. Oikonen,et al.  Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  P. Tak,et al.  Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis , 2012, Annals of the rheumatic diseases.

[12]  P. Tak,et al.  Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool , 2012, Annals of the rheumatic diseases.

[13]  P. Tak,et al.  Clinical and epidemiological research , 2011 .

[14]  R. Boellaard,et al.  18F-FDG PET as a Tool to Predict the Clinical Outcome of Infliximab Treatment of Rheumatoid Arthritis: An Explorative Study , 2011, The Journal of Nuclear Medicine.

[15]  B Combe,et al.  Extended Report , 2022 .

[16]  P. Jurek,et al.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.

[17]  I. Vajtai,et al.  Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis , 2009, Arthritis research & therapy.

[18]  A. Zwinderman,et al.  Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response , 2007, Annals of the rheumatic diseases.

[19]  J. Tuscano,et al.  Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. , 2005, The Journal of rheumatology.

[20]  Marjolein Vinkenoog,et al.  Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis , 2005, Arthritis research & therapy.

[21]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[22]  R. Boellaard,et al.  89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Terry Jones,et al.  The role of positron emission tomography within the spectrum of medical imaging , 1996, European Journal of Nuclear Medicine.

[24]  F. Magyari,et al.  International Workshop on PET in Lymphoma , 2014 .

[25]  B. Dijkmans,et al.  Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. , 2012, Arthritis and rheumatism.

[26]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.